Zeng Yun-Zhu, Zhang Yong-Qu, Lin Xue-Qiong, Chen Jiong-Yu, Zhang Fan, Zhu Jian-Ling, Wei Xiao-Long
Department of Pathology, Cancer Hospital of Shantou University Medical College, Shantou, China.
Department of Breast-Thyroid-Surgery, Xiang'an Hospital of Xiamen University, Xiamen, China.
Transl Cancer Res. 2021 Jan;10(1):210-222. doi: 10.21037/tcr-20-2498.
Lymphatic metastasis is one of the main factors affecting prognosis in esophageal squamous cell carcinoma (ESCC). Vascular endothelial growth factor-C (VEGF-C) is an important factor that promotes lymphangiogenesis. Survivin also plays a significant role in lymphatic invasion. However, the role and mechanism of their co-expression are still unclear in ESCC. The purpose of this study was to investigate whether the co-expression of VEGF-C and survivin could be a potential marker to predict patient prognosis and survival in ESCC.
The levels of VEGF-C, vascular endothelial growth factor receptor 3 (VEGFR-3), survivin, and Ki-67 were determined by immunohistochemistry (IHC) in 97 ESCC patient tumors. The correlations of co-expression of VEGF-C and survivin with pathological features and survival results were also assessed.
High VEGF-C expression was observed in 64.9% of the patients and significantly correlated with T stage (P=0.024), node status (P=0.038), and lymph node metastasis (P=0.015). High survivin expression was significantly associated with T stage (P=0.013), N stage (P=0.016), lymph node metastasis (P=0.005), and differentiation (P=0.044) in 67.0% of the patients. Co-expression of VEGF-C and survivin (V+S+) was significantly associated with T stage (P<0.001), N stage (P=0.015), lymph node metastasis (P=0.003), differentiation (P=0.0045), and Ki-67 levels (P=0.024). High expression of VEGF-C or survivin was associated significantly with worse disease-free survival (DFS) and overall survival (OS) (P<0.05). Moreover, the V+S+ group had a worse DFS (P<0.001) and OS (P=0.001) than any other group (i.e., V-S-, V+S-, V-S+). Furthermore, multivariate DFS analyses (95% CI: 1.147-2.220, P=0.006) and multivariate OS analyses (95% CI: 1.080-2.193, P=0.017) revealed that co-expression of VEGF-C and survivin was an independent prognostic factor in ESCC patients.
Co-expression of VEGF-C and survivin was predictive of poor prognosis in ESCC. Combined detection of VEGF-C and survivin could represent a feasible and effective marker to predict the prognosis and survival of ESCC patients.
淋巴转移是影响食管鳞状细胞癌(ESCC)预后的主要因素之一。血管内皮生长因子-C(VEGF-C)是促进淋巴管生成的重要因子。Survivin在淋巴浸润中也起重要作用。然而,它们在ESCC中共表达的作用和机制仍不清楚。本研究的目的是探讨VEGF-C和survivin的共表达是否可能是预测ESCC患者预后和生存的潜在标志物。
采用免疫组织化学(IHC)法检测97例ESCC患者肿瘤组织中VEGF-C、血管内皮生长因子受体3(VEGFR-3)、survivin和Ki-67的水平。还评估了VEGF-C和survivin共表达与病理特征及生存结果的相关性。
64.9%的患者VEGF-C表达较高,且与T分期(P=0.024)、淋巴结状态(P=0.038)和淋巴结转移(P=0.015)显著相关。67.0%的患者survivin高表达与T分期(P=0.013)、N分期(P=0.016)、淋巴结转移(P=0.005)和分化程度(P=0.044)显著相关。VEGF-C和survivin共表达(V+S+)与T分期(P<(0.001)、N分期(P=0.015)、淋巴结转移(P=(0.003)、分化程度(P=(0.0045)和Ki-67水平(P=0.024)显著相关。VEGF-C或survivin高表达与无病生存期(DFS)和总生存期(OS)较差显著相关(P<0.05)。此外,V+S+组的DFS(P<0.001)和OS(P=0.001)比其他任何组(即V-S-、V+S-、V-S+)都差。此外,多因素DFS分析(95%CI:1.147-2.220,P=0.006)和多因素OS分析(95%CI:1.080-2.193,P=0.017)显示,VEGF-C和survivin的共表达是ESCC患者的独立预后因素。
VEGF-C和survivin的共表达可预测ESCC预后不良。联合检测VEGF-C和survivin可能是预测ESCC患者预后和生存的一种可行且有效的标志物。